23 Jul, 2026
According to Straits Research, the global anatomic pathology market size was valued at $38.66 billion in 2025 and is expected to grow from $41.64 billion in 2026 to $76.42 billion by 2034, registering a CAGR of 7.89% during the forecast period (2026–2034).
The anatomic pathology market is being transformed by technological integration, precision medicine, and emerging diagnostic innovations. Digital pathology platforms and automated slide scanners are streamlining workflows, enabling high-resolution imaging, AI-assisted analysis, and remote diagnostics, which reduce turnaround times and improve diagnostic accuracy, particularly in oncology and high-throughput labs. The rising demand for companion diagnostics is further driving the market, as these tests enable personalized treatment plans By tumor characteristics and genetic markers, thereby minimizing ineffective therapies and associated costs. Collaboration among pathologists, pharmaceutical companies, and diagnostic developers ensures the development of accurate, reproducible tests that meet regulatory standards. Market growth is also fueled by increased research and development, especially in oncology, where novel biomarkers and diagnostic tools enhance disease detection and monitoring.
However, high costs of advanced equipment, such as digital scanners, molecular diagnostics platforms, and histopathology instruments, limit accessibility, particularly for resource-constrained labs. Emerging technologies, such as next-generation sequencing (NGS), artificial intelligence, and machine learning, present significant opportunities, enabling multiplex gene analysis, monitoring circulating tumor DNA, and linking complex data to clinical outcomes. These innovations support precision medicine, improve patient care, and enhance efficiency, positioning the anatomic pathology market for substantial growth despite cost-related challenges.
sales@straitsresearch.com